[
  {
    "ts": null,
    "headline": "Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights",
    "summary": "SAN DIEGO, August 07, 2025--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.",
    "url": "https://finnhub.io/api/news?id=8fc3f3072cd67f390a43827491cd1cdec469be05dd4aa091b493ee9815b9fb35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754596860,
      "headline": "Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights",
      "id": 136266754,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "SAN DIEGO, August 07, 2025--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.",
      "url": "https://finnhub.io/api/news?id=8fc3f3072cd67f390a43827491cd1cdec469be05dd4aa091b493ee9815b9fb35"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs Reduced the PT on Merck & Co., Inc. (MRK), Kept a Buy Rating",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the Best Stocks to Invest in for High Returns. On July 30, Goldman Sachs analyst Asad Haider maintained a Buy rating on Merck & Co., Inc. (NYSE:MRK) while reducing the price target from $99 to $94. The analyst noted that despite recent complexities in the company’s financial update […]",
    "url": "https://finnhub.io/api/news?id=b41af0d6155a00b991b6974c5e87a8a62b93774b631bf4b753ce2e12b2b944a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754584802,
      "headline": "Goldman Sachs Reduced the PT on Merck & Co., Inc. (MRK), Kept a Buy Rating",
      "id": 136266755,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the Best Stocks to Invest in for High Returns. On July 30, Goldman Sachs analyst Asad Haider maintained a Buy rating on Merck & Co., Inc. (NYSE:MRK) while reducing the price target from $99 to $94. The analyst noted that despite recent complexities in the company’s financial update […]",
      "url": "https://finnhub.io/api/news?id=b41af0d6155a00b991b6974c5e87a8a62b93774b631bf4b753ce2e12b2b944a8"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=1412ec770132ab2452924d2a4a61ec4a47ae4de35f82ef680202fa57c2bd8a53",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754584440,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 136297202,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=1412ec770132ab2452924d2a4a61ec4a47ae4de35f82ef680202fa57c2bd8a53"
    }
  },
  {
    "ts": null,
    "headline": "Why Merck (MRK) is a Top Value Stock for the Long-Term",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=14640076fe0c79f950be0c8936b6dd212652b0ca01083e6d5bf057d955f30ebc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754574003,
      "headline": "Why Merck (MRK) is a Top Value Stock for the Long-Term",
      "id": 136266756,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=14640076fe0c79f950be0c8936b6dd212652b0ca01083e6d5bf057d955f30ebc"
    }
  },
  {
    "ts": null,
    "headline": "United States Vaccines Market Insights and Forecasts 2024 & 2025-2033 | Rising Infectious Disease Burden, Robust Funding and Regulatory Support Accelerate Innovation",
    "summary": "The US vaccines market, valued at $29.5B in 2024, is projected to reach $60B by 2033, at a CAGR of 8.2%. Key growth drivers include rising infectious diseases and biotech advancements. Comprehensive analysis covers market dynamics, regulatory environment, and top players like Pfizer and Merck. U.S. Vaccines Market U.S. Vaccines Market Dublin, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The \"United States Vaccines Market Size, Top 47 Vaccines Brand In-depth Analysis, Insights, and Forecasts to 2033\" report",
    "url": "https://finnhub.io/api/news?id=a3c949f863a6b4b6fd050851bb0dfe742b06154922c54082d4e792b0073a4c40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754574000,
      "headline": "United States Vaccines Market Insights and Forecasts 2024 & 2025-2033 | Rising Infectious Disease Burden, Robust Funding and Regulatory Support Accelerate Innovation",
      "id": 136266757,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The US vaccines market, valued at $29.5B in 2024, is projected to reach $60B by 2033, at a CAGR of 8.2%. Key growth drivers include rising infectious diseases and biotech advancements. Comprehensive analysis covers market dynamics, regulatory environment, and top players like Pfizer and Merck. U.S. Vaccines Market U.S. Vaccines Market Dublin, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The \"United States Vaccines Market Size, Top 47 Vaccines Brand In-depth Analysis, Insights, and Forecasts to 2033\" report",
      "url": "https://finnhub.io/api/news?id=a3c949f863a6b4b6fd050851bb0dfe742b06154922c54082d4e792b0073a4c40"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know",
    "summary": "Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=e28f597f7005d75e8ebe6086004655d35ac0a01eea947d00566fff4eca93c1ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754571605,
      "headline": "Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know",
      "id": 136266758,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=e28f597f7005d75e8ebe6086004655d35ac0a01eea947d00566fff4eca93c1ff"
    }
  },
  {
    "ts": null,
    "headline": "United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda",
    "summary": "The United States Pharmaceutical Market is projected to reach $979.25 billion by 2033, from $638.86 billion in 2024, at a CAGR of 4.86% (2025-2033). Growth is driven by rising chronic diseases, demand for innovative medicines, and advanced biotech solutions. High R&D investments in oncology, neurology, and infectious diseases fuel the market, alongside robust government support and insurance coverage. California and New York lead in R&D and distribution. Key challenges include regulatory complex",
    "url": "https://finnhub.io/api/news?id=c5faab32289036b61d1de41f603a0cb2c73c4612692dcf7386f42a8f151806d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754570460,
      "headline": "United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda",
      "id": 136246157,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The United States Pharmaceutical Market is projected to reach $979.25 billion by 2033, from $638.86 billion in 2024, at a CAGR of 4.86% (2025-2033). Growth is driven by rising chronic diseases, demand for innovative medicines, and advanced biotech solutions. High R&D investments in oncology, neurology, and infectious diseases fuel the market, alongside robust government support and insurance coverage. California and New York lead in R&D and distribution. Key challenges include regulatory complex",
      "url": "https://finnhub.io/api/news?id=c5faab32289036b61d1de41f603a0cb2c73c4612692dcf7386f42a8f151806d8"
    }
  },
  {
    "ts": null,
    "headline": "August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys",
    "summary": "Discover the top Dow dividend stocks for steady gains by 2026.",
    "url": "https://finnhub.io/api/news?id=5b4324cf7aa0db1844e537f7ec31acf7b22ccb8eb46fc4995dc453357313aa09",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754569431,
      "headline": "August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys",
      "id": 136249581,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/481098702/image_481098702.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover the top Dow dividend stocks for steady gains by 2026.",
      "url": "https://finnhub.io/api/news?id=5b4324cf7aa0db1844e537f7ec31acf7b22ccb8eb46fc4995dc453357313aa09"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "0804 GMT – Germany’s Merck KGaA reported second-quarter results that fell short of expectations at the top and bottom lines due to a weaker performance from the group’s electronics segment, Morgan Stanley analysts say in a research note.  The German life-sciences and chemicals group reported net sales that were 1% below consensus estimates, and Ebitda before exceptional items that missed forecasts by 4%, the analysts say.  Stronger expectations for Merck’s life-science and healthcare segments lead the group to raise its full-year guidance for organic growth in adjusted Ebitda, Morgan Stanley says.",
    "url": "https://finnhub.io/api/news?id=523850afccd8048462e9f06c94d7d358b5de2f900eb4cdfefe865b11cbc7cbb7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754565240,
      "headline": "Health Care Roundup: Market Talk",
      "id": 136246277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "0804 GMT – Germany’s Merck KGaA reported second-quarter results that fell short of expectations at the top and bottom lines due to a weaker performance from the group’s electronics segment, Morgan Stanley analysts say in a research note.  The German life-sciences and chemicals group reported net sales that were 1% below consensus estimates, and Ebitda before exceptional items that missed forecasts by 4%, the analysts say.  Stronger expectations for Merck’s life-science and healthcare segments lead the group to raise its full-year guidance for organic growth in adjusted Ebitda, Morgan Stanley says.",
      "url": "https://finnhub.io/api/news?id=523850afccd8048462e9f06c94d7d358b5de2f900eb4cdfefe865b11cbc7cbb7"
    }
  },
  {
    "ts": null,
    "headline": "Germany’s Merck Raises Earnings Growth Guidance, But Turns Cautious on Sales",
    "summary": "The group lifted its full-year guidance for growth in underlying earnings, due to better prospects for its life-sciences and healthcare segments, but was cautious on sales.",
    "url": "https://finnhub.io/api/news?id=01302340594b0cd4c11a8d52fcecb8deca31bc85347b775f8a349de77dd9f28b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754545020,
      "headline": "Germany’s Merck Raises Earnings Growth Guidance, But Turns Cautious on Sales",
      "id": 136246278,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The group lifted its full-year guidance for growth in underlying earnings, due to better prospects for its life-sciences and healthcare segments, but was cautious on sales.",
      "url": "https://finnhub.io/api/news?id=01302340594b0cd4c11a8d52fcecb8deca31bc85347b775f8a349de77dd9f28b"
    }
  }
]